Baxter Licenses Platelet System To Haemonetics, Anticipates 2003 Approval
This article was originally published in The Gray Sheet
Executive Summary
Baxter expects FDA approval by mid-2003 for its Intercept platelet blood screening system, licensed to Haemonetics in a deal announced Dec. 10
You may also be interested in...
Baxter/Cerus Pathogen Inactivation PMA Set Back Two Years For More Data
Baxter/Cerus expects the supplemental pivotal trial of its Intercept blood platelet pathogen inactivation system to take 15-18 months to complete
Baxter/Cerus Pathogen Inactivation PMA Set Back Two Years For More Data
Baxter/Cerus expects the supplemental pivotal trial of its Intercept blood platelet pathogen inactivation system to take 15-18 months to complete
Vitex Takes On Baxter: Will Parallel Study Favor Swift Inactine Approval?
A parallel arm design for Vitex' Phase III pivotal trial testing the Inactine red blood cell pathogen inactivation system in chronic anemia patients positions Vitex to be the first to market in the U.S., according to the firm